| [1] | Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, et al. (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266: 1865–1869. doi: 10.1126/science.7997879
|
| [2] | Ganem D (2010) KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest 120: 939–949. doi: 10.1172/jci40567
|
| [3] | Mesri EA, Cesarman E, Boshoff C (2010) Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 10: 707–719. doi: 10.1038/nrc2888
|
| [4] | Casper C (2011) The increasing burden of HIV-associated malignancies in resource-limited regions. Annu Rev Med 62: 157–170. doi: 10.1146/annurev-med-050409-103711
|
| [5] | An FQ, Folarin HM, Compitello N, Roth J, Gerson SL, et al. (2006) Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol 80: 4833–4846. doi: 10.1128/jvi.80.10.4833-4846.2006
|
| [6] | Ashlock BA, Ma Q, Isaac B, Mesri EA (2014) Productively infected murine Kaposi's sarcoma-like tumors define new animal models for studying and targeting KSHV oncogenesis and replication. PLoS ONE In press. doi: 10.1371/journal.pone.0087324
|
| [7] | Mesri EA, Feitelson MA, Munger K (2014) Human Viral Oncogenesis: A Cancer Hallmarks Analysis. Cell Host Microbe 15: 266–282. doi: 10.1016/j.chom.2014.02.011
|
| [8] | Cesarman E (2014) Gammaherpesviruses and lymphoproliferative disorders. Annu Rev Pathol 9: 349–372. doi: 10.1146/annurev-pathol-012513-104656
|
| [9] | Martin JN (2011) Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and Kaposi sarcoma. Adv Dent Res 23: 76–78. doi: 10.1177/0022034511399913
|
| [10] | Cancian L, Hansen A, Boshoff C (2013) Cellular origin of Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus-induced cell reprogramming. Trends Cell Biol 23: 421–432. doi: 10.1016/j.tcb.2013.04.001
|
| [11] | Browning PJ, Sechler JM, Kaplan M, Washington RH, Gendelman R, et al. (1994) Identification and culture of Kaposi's sarcoma-like spindle cells from the peripheral blood of human immunodeficiency virus-1-infected individuals and normal controls. Blood 84: 2711–2720.
|
| [12] | Barozzi P, Luppi M, Facchetti F, Mecucci C, Alu M, et al. (2003) Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med 9: 554–561. doi: 10.1038/nm862
|
| [13] | Mutlu AD, Cavallin LE, Vincent L, Chiozzini C, Eroles P, et al. (2007) In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma. Cancer Cell 11: 245–258. doi: 10.1016/j.ccr.2007.01.015
|
| [14] | Jones T, Ye F, Bedolla R, Huang Y, Meng J, et al. (2012) Direct and efficient cellular transformation of primary rat mesenchymal precursor cells by KSHV. J Clin Invest 122: 1076–1081. doi: 10.1172/jci58530
|
| [15] | Radkov SA, Kellam P, Boshoff C (2000) The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 6: 1121–1127.
|
| [16] | Swanton C, Mann DJ, Fleckenstein B, Neipel F, Peters G, et al. (1997) Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 390: 184–187.
|
| [17] | Guasparri I, Keller SA, Cesarman E (2004) KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med 199: 993–1003. doi: 10.1084/jem.20031467
|
| [18] | Zhu Y, Haecker I, Yang Y, Gao SJ, Renne R (2013) gamma-Herpesvirus-encoded miRNAs and their roles in viral biology and pathogenesis. Curr Opin Virol 3: 266–275. doi: 10.1016/j.coviro.2013.05.013
|
| [19] | Coscoy L (2007) Immune evasion by Kaposi's sarcoma-associated herpesvirus. Nat Rev Immunol 7: 391–401. doi: 10.1038/nri2076
|
| [20] | Ma Q, Cavallin LE, Leung HJ, Chiozzini C, Goldschmidt-Clermont PJ, et al. (2013) A role for virally induced reactive oxygen species in Kaposi's sarcoma herpesvirus tumorigenesis. Antioxid Redox Signal 18: 80–90. doi: 10.1089/ars.2012.4584
|
| [21] | Bais C, Santomasso B, Coso O, Arvanitakis L, Raaka EG, et al. (1998) G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391: 86–89. doi: 10.1097/00042560-199804010-00079
|
| [22] | Bais C, Van Geelen A, Eroles P, Mutlu A, Chiozzini C, et al. (2003) Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cell 3: 131–143. doi: 10.1016/s1535-6108(03)00024-2
|
| [23] | Jensen KK, Manfra DJ, Grisotto MG, Martin AP, Vassileva G, et al. (2005) The human herpes virus 8-encoded chemokine receptor is required for angioproliferation in a murine model of Kaposi's sarcoma. J Immunol 174: 3686–3694. doi: 10.4049/jimmunol.174.6.3686
|
| [24] | Sodhi A, Chaisuparat R, Hu J, Ramsdell AK, Manning BD, et al. (2006) The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 10: 133–143. doi: 10.1016/j.ccr.2006.05.026
|
| [25] | Wang L, Dittmer DP, Tomlinson CC, Fakhari FD, Damania B (2006) Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. Cancer Res 66: 3658–3666. doi: 10.1158/0008-5472.can-05-3680
|
| [26] | Chen D, Sandford G, Nicholas J (2009) Intracellular signaling mechanisms and activities of human herpesvirus 8 interleukin-6. J Virol 83: 722–733. doi: 10.1128/jvi.01517-08
|
| [27] | Chang HH, Ganem D (2013) A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity. Cell Host Microbe 13: 429–440. doi: 10.1016/j.chom.2013.03.009
|
| [28] | Montaner S, Sodhi A, Ramsdell AK, Martin D, Hu J, et al. (2006) The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. Cancer Res 66: 168–174. doi: 10.1158/0008-5472.can-05-1026
|
| [29] | Aoki Y, Tosato G (2007) Interactions between HIV-1 Tat and KSHV. Curr Top Microbiol Immunol 312: 309–326. doi: 10.1007/978-3-540-34344-8_12
|
| [30] | Bihl F, Mosam A, Henry LN, Chisholm JV 3rd, Dollard S, et al. (2007) Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma. AIDS 21: 1245–1252. doi: 10.1097/qad.0b013e328182df03
|
| [31] | Roy D, Sin SH, Lucas A, Venkataramanan R, Wang L, et al. (2013) mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis. Cancer Res 73: 2235–2246. doi: 10.1158/0008-5472.can-12-1851
|
| [32] | Ma Q, Cavallin LE, Yan B, Zhu S, Duran EM, et al. (2009) Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi's sarcoma. Proc Natl Acad Sci U S A 106: 8683–8688. doi: 10.1073/pnas.0812688106
|
| [33] | Liu R, Li X, Tulpule A, Zhou Y, Scehnet JS, et al. (2010) KSHV-induced notch components render endothelial and mural cell characteristics and cell survival. Blood 115: 887–895. doi: 10.1182/blood-2009-08-236745
|
| [34] | Croci DO, Salatino M, Rubinstein N, Cerliani JP, Cavallin LE, et al. (2012) Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med 209: 1985–2000. doi: 10.1084/jem.20111665
|
| [35] | Dittmer DP, Krown SE (2007) Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus. Curr Opin Oncol 19: 452–457. doi: 10.1097/cco.0b013e3281eb8ea7
|
| [36] | Nguyen HQ, Magaret AS, Kitahata MM, Van Rompaey SE, Wald A, et al. (2008) Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 22: 937–945. doi: 10.1097/qad.0b013e3282ff6275
|
| [37] | Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, et al. (1999) Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 340: 1063–1070. doi: 10.1056/nejm199904083401402
|
| [38] | Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B (2004) Antitumour effects of antiretroviral therapy. Nat Rev Cancer 4: 861–875. doi: 10.1038/nrc1479
|
| [39] | Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, et al. (2005) Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352: 1317–1323. doi: 10.1056/nejmoa042831
|
| [40] | Krown SE, Roy D, Lee JY, Dezube BJ, Reid EG, et al. (2012) Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. J Acquir Immune Defic Syndr 59: 447–454. doi: 10.1097/qai.0b013e31823e7884
|
| [41] | Koon HB, Bubley GJ, Pantanowitz L, Masiello D, Smith B, et al. (2005) Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 23: 982–989. doi: 10.1200/jco.2005.06.079
|
| [42] | Koon HB, Krown SE, Lee JY, Honda K, Rapisuwon S, et al. (2014) Phase II Trial of Imatinib in AIDS-Associated Kaposi's Sarcoma: AIDS Malignancy Consortium Protocol 042. J Clin Oncol 32: 402–408. doi: 10.1200/jco.2012.48.6365
|
